| (Values in U.S. Thousands) | Jul, 2025 | Jul, 2024 | Jul, 2023 | Jul, 2022 | Jul, 2021 |
| Sales | 920 | 640 | 280 | 410 | 3,970 |
| Sales Growth | +43.75% | +128.57% | -31.71% | -89.67% | -19.14% |
| Net Income | -30,520 | -34,410 | -1,880 | -124,660 | -24,540 |
| Net Income Growth | +11.30% | -1,730.32% | +98.49% | -407.99% | -135.51% |
Rafael Holdings Inc (RFL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Rafael Holdings Inc. manufactures metabolic oncology drugs to treat cancer. The company's product pipeline consists of CPI-613, CPI-618, CPI-1826 and CPI-3220 which are in clinical stages. Rafael Holdings Inc. is based in Newark, United States.
Fiscal Year End Date: 07/31